HSK42360 clinical trials
Also written HSK42360.
How each study uses HSK42360 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HSK42360 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HSK42360
- 2
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses HSK42360 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal CancerRecruitingPhase 1/2Haisco Pharmaceutical Group Co., Ltd.NCT07790510Written as HSK42360-Na Tablets
- Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 MutationRecruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07561554Written as HSK42360-Na
- Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 MutationRecruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07158710Written as HSK42360
- Phase I Study of HSK42360 in Solid Tumors With BRAF V600 MutationRecruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06536400Written as HSK42360